News
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...
Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...
Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...
Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...
Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, expectations were $-2.99. Operator: Good day, and thank you for standing by. Welcome ...
9d
MedPage Today on MSNFDA's Top Vaccine Official Resigns
A fter just a few controversial months, Vinay Prasad, MD, MPH, has stepped down as director of FDA's Center for Biologics Evaluation and Research (CBER).
The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...
HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...
In the video posted on X, Kennedy claimed mRNA vaccines were ineffective against mutated versions of the virus and revealed HHS is planning to reallocate the funding to research whole-virus vaccines, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results